-
2 months ago | 
onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli
OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences. Video content above is prompted by the following:Briefly discuss how you approach treatment for patients with HER2-ultralow metastatic breast cancer.
-
2 months ago | 
onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli
OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations. Video content above is prompted by the following:Please discuss the recent findings from the DESTINY-Breast06 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.
-
Jan 22, 2025 | 
onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli
OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates. Video content above is prompted by the following:Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer.
-
Jan 21, 2025 | 
nature.com | Fatima Cardoso |Heather L. McArthur |Javier Cortés |Nadia Harbeck |Melinda L. Telli |David W. Cescon | +3 more
AbstractAddition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition of neoadjuvant pembrolizumab to chemotherapy would improve outcomes in high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer remains unclear.
-
Aug 10, 2024 | 
cancernetwork.com | Erika Hamilton |Rinath Jeselsohn |Sara A. Hurvitz |Dejan Juric |Hyo S Han |Melinda L. Telli | +8 more
BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeras (PROTAC) estrogen receptor (ER) degrader. In a phase 1/2 study (NCT04072952), vepdegestrant monotherapy had a favorable safety profile and encouraging clinical activity with robust ER degradation. The phase 1b cohort of this study is evaluating vepdegestrant plus the CDK4/6inhibitor palbociclib.
-
Aug 4, 2024 | 
cancernetwork.com | Sara A. Hurvitz |Anne F. Schott |Cynthia X. MA |Rita Nanda |George Zahrah |Natasha Hunter | +10 more
BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeric (PROTAC) estrogen receptor (ER) degrader with activity toward wild-type and mutant ER. The phase 2 expansion (VERITAC) of a phase 1/2 study tested 2 vepdegestrant doses (200 mg once daily and 500 mg once daily) in heavily pretreated patients with ER+/HER2-negative (HER2–) advanced breast cancer.
-
Jul 29, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Unmet Needs and Future Direction in HER2+ Breast CancerThe panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.
-
Jul 29, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBCFocusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.
-
Jul 22, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
OpinionVideoJuly 22, 2024Author(s):Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions. Video content above is prompted by the following questions:Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
-
Jul 22, 2024 | 
onclive.com | Joyce O'Shaughnessy |Melinda L. Telli |Aditya Bardia |Ian Krop |Kandace P. McGuire
OpinionVideoJuly 22, 2024Author(s):Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD. Video content above is prompted by the following questions:What has your clinical experience been monitoring for T-DXd-related interstitial lung disease (ILD)?
